Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C14H12O3 |
| Molecular Weight | 228.2433 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC2=CC3=C(OC(=O)C=C3C)C(C)=C2O1
InChI
InChIKey=FMHHVULEAZTJMA-UHFFFAOYSA-N
InChI=1S/C14H12O3/c1-7-4-12(15)17-14-9(3)13-10(6-11(7)14)5-8(2)16-13/h4-6H,1-3H3
| Molecular Formula | C14H12O3 |
| Molecular Weight | 228.2433 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: http://www.drugbank.ca/drugs/DB04571Curator's Comment: description was created based on several sources, including: http://www.drugs.com/cons/trioxsalen.html
Sources: http://www.drugbank.ca/drugs/DB04571
Curator's Comment: description was created based on several sources, including: http://www.drugs.com/cons/trioxsalen.html
Trioxsalen (trimethylpsoralen, trioxysalen or trisoralen) is a furanocoumarin and a psoralen derivative. It is obtained from several plants, mainly Psoralea corylifolia. Like other psoralens it causes photosensitization of the skin. It is administered either topically or orally in conjunction with UV-A (the least damaging form of ultraviolet light) for phototherapy treatment of vitiligo1 and hand eczema.2 After photoactivation it creates interstrand cross-links in DNA, which can cause programmed cell death unless repaired by cellular mechanisms. In research it can be conjugated to dyes for confocal microscopy and used to visualize sites of DNA damage.3 The compound is also being explored for development of antisense oligonucleotides that can be cross-linked specifically to a mutant mRNA sequence without affecting normal transcripts differing at even a single base pair.Trioxsalen was discontinued by the manufacturer in December 2002.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2311221 Sources: http://www.ncbi.nlm.nih.gov/pubmed/7499429 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
Sources: https://www.drugs.com/cons/trisoralen.html |
Primary | TRISORALEN Approved UseTrioxsalen Launch Date1965 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
12.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6177169/ |
0.6 mg/kg single, oral dose: 0.6 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
TRIOXSALEN plasma | Homo sapiens population: UNHEALTHY age: UNKNOWN sex: FEMALE / MALE food status: UNKNOWN |
|
31 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7236507/ |
400 mg 1 times / day unknown, oral dose: 400 mg route of administration: Oral experiment type: UNKNOWN co-administered: |
TRIOXSALEN serum | Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: FED |
|
3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6155034/ |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
TRIOXSALEN plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2% |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
TRIOXSALEN serum | Homo sapiens |
PubMed
| Title | Date | PubMed |
|---|---|---|
| RACK-1 acts with Rac GTPase signaling and UNC-115/abLIM in Caenorhabditis elegans axon pathfinding and cell migration. | 2010-11-18 |
|
| Analysis of active and inactive X chromosome architecture reveals the independent organization of 30 nm and large-scale chromatin structures. | 2010-11-12 |
|
| Conserved genes act as modifiers of invertebrate SMN loss of function defects. | 2010-10-28 |
|
| A developmental timing switch promotes axon outgrowth independent of known guidance receptors. | 2010-08-05 |
|
| Multivesicular body formation requires OSBP-related proteins and cholesterol. | 2010-08-05 |
|
| Structural determinants of photoreactivity of triplex forming oligonucleotides conjugated to psoralens. | 2010-07-25 |
|
| Rapid sampling of molecules via skin for diagnostic and forensic applications. | 2010-07 |
|
| Photoallergic contact dermatitis to 8-methoxypsoralen in Ficus carica. | 2010-06 |
|
| Whole-genome profiling of mutagenesis in Caenorhabditis elegans. | 2010-06 |
|
| Topical treatment in vitiligo and the potential uses of new drug delivery systems. | 2010-05-07 |
|
| Two very long chain fatty acid acyl-CoA synthetase genes, acs-20 and acs-22, have roles in the cuticle surface barrier in Caenorhabditis elegans. | 2010-01-25 |
|
| Trioxsalen derivatives with lipoxygenase inhibitory activity. | 2009-12 |
|
| The germinal center kinase GCK-1 is a negative regulator of MAP kinase activation and apoptosis in the C. elegans germline. | 2009-10-14 |
|
| Role of tacrolimus (FK506) 0.1% ointment WW in vitiligo in children and imperatives of combine therapy with Trioxsalen and Silymarin suspension in progressive vitiligo. | 2009-10 |
|
| Cancer risk in hospitalised psoriasis patients: a follow-up study in Sweden. | 2009-05-05 |
|
| Electron microscopy methods for studying in vivo DNA replication intermediates. | 2009 |
|
| Nematode homologue of PQBP1, a mental retardation causative gene, is involved in lipid metabolism. | 2009 |
|
| An unexpectedly high degree of specialization and a widespread involvement in sterol metabolism among the C. elegans putative aminophospholipid translocases. | 2008-10-02 |
|
| The HLH-6 transcription factor regulates C. elegans pharyngeal gland development and function. | 2008-10 |
|
| 3-Methyladenine DNA glycosylase is important for cellular resistance to psoralen interstrand cross-links. | 2008-08-02 |
|
| DNA interstrand crosslinks repair in mammalian cells. | 2008-06-07 |
|
| Application of TILLING and EcoTILLING as Reverse Genetic Approaches to Elucidate the Function of Genes in Plants and Animals. | 2008-06 |
|
| BINOL-amino acid conjugates as triggerable carriers of DNA-targeted potent photocytotoxic agents. | 2007-12-27 |
|
| Counting mutagenized genomes and optimizing genetic screens in Caenorhabditis elegans. | 2007-11-07 |
|
| In vivo footprint of a picornavirus internal ribosome entry site reveals differences in accessibility to specific RNA structural elements. | 2007-11 |
|
| Food deprivation attenuates seizures through CaMKII and EAG K+ channels. | 2007-09 |
|
| German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version). | 2007-06 |
|
| Psoralen conjugates for visualization of genomic interstrand cross-links localized by laser photoactivation. | 2007-03-22 |
|
| Regulation of Caenorhabditis elegans body size and male tail development by the novel gene lon-8. | 2007-03-20 |
|
| Specific apoptosis induction in human papillomavirus-positive cervical carcinoma cells by photodynamic antisense regulation. | 2007 |
|
| Synthesis and biological in vitro evaluation of novel PEG-psoralen conjugates. | 2006-12 |
|
| TILLING is an effective reverse genetics technique for Caenorhabditis elegans. | 2006-10-18 |
|
| Permeability of psoralen derivatives in lipid membranes. | 2006-10-01 |
|
| Enhanced repair of DNA interstrand crosslinks in S phase. | 2006-03-06 |
|
| Properties of novel antisense oligonucleotides containing 2'-O-modified adenosine with a photo-reactive group. | 2006 |
|
| Occupational allergic contact dermatitis disseminated from multifunctional acrylates in ultraviolet-cured lacquers. | 2006 |
|
| Inhibition of interferon-gamma signaling by a mercurio-substituted dihydropsoralen in murine keratinocytes. | 2005-12-05 |
|
| Psoralen and coumarin photochemistry in HSA complexes and DMPC vesicles. | 2005-09-10 |
|
| Repair of DNA interstrand crosslinks may take place at the nuclear matrix. | 2005-09-01 |
|
| Psoralen photocrosslinking, a tool to study the chromatin structure of RNA polymerase I--transcribed ribosomal genes. | 2005-08 |
|
| Spectral study of interactions of 4,8,4'-trimethylpsoralen and 4,4'-dimethylangelicin dyes with DNA. | 2005-07 |
|
| Photoreaction of skin-sensitizing trimethyl psoralen with lipid membrane models. | 2005-05-11 |
|
| Disappearance of nucleosome positioning in mitotic chromatin in vivo. | 2005-04-15 |
|
| Interplay between human high mobility group protein 1 and replication protein A on psoralen-cross-linked DNA. | 2005-03-22 |
|
| 5-(3-Phenylpropoxy)psoralen and 5-(4-phenylbutoxy)psoralen: mechanistic studies on phototoxicity. | 2005-03 |
|
| Synthesis and properties of photo-reactive antisense oligonucleotides containing 2'-O-psoralen-conjugated adenosine. | 2005 |
|
| Identification of ciliated sensory neuron-expressed genes in Caenorhabditis elegans using targeted pull-down of poly(A) tails. | 2005 |
|
| Comparison of oral psoralen-UV-A with a portable tanning unit at home vs hospital-administered bath psoralen-UV-A in patients with chronic hand eczema: an open-label randomized controlled trial of efficacy. | 2004-12 |
|
| Tandem mass spectrometry for the determination of the sites of DNA interstrand cross-link. | 2004-11 |
|
| Psoralen derivatives and longwave ultraviolet irradiation are active in vitro against human melanoma cell line. | 2004-10-25 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.drugs.com/cons/trioxsalen.html
for vitiligo:
Adults and children 12 years of age and over—20 to 40 milligrams (mg) taken two to four hours before ultraviolet light A (UVA) exposure. This treatment (trioxsalen and UVA) is given two or three times a week with the treatments spaced at least forty-eight hours apart.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:31:05 GMT 2025
by
admin
on
Mon Mar 31 18:31:05 GMT 2025
|
| Record UNII |
Y6UY8OV51T
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NDF-RT |
N0000007909
Created by
admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
|
||
|
NDF-RT |
N0000175879
Created by
admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
|
||
|
WHO-VATC |
QD05AD01
Created by
admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
|
||
|
WHO-ATC |
D05AD01
Created by
admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
|
||
|
WHO-ATC |
D05BA01
Created by
admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
|
||
|
NDF-RT |
N0000007909
Created by
admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
|
||
|
NCI_THESAURUS |
C29708
Created by
admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
|
||
|
WHO-VATC |
QD05BA01
Created by
admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
|
||
|
NDF-RT |
N0000007909
Created by
admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID3023716
Created by
admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
|
PRIMARY | |||
|
SUB11318MIG
Created by
admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
|
PRIMARY | |||
|
100000076929
Created by
admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
|
PRIMARY | |||
|
2759
Created by
admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
|
PRIMARY | |||
|
1693009
Created by
admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
|
PRIMARY | |||
|
m11177
Created by
admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
|
PRIMARY | Merck Index | ||
|
3902-71-4
Created by
admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
|
PRIMARY | |||
|
CHEMBL1475
Created by
admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
|
PRIMARY | |||
|
223-459-0
Created by
admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
|
PRIMARY | |||
|
10844
Created by
admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
|
PRIMARY | RxNorm | ||
|
C66640
Created by
admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
|
PRIMARY | |||
|
71047
Created by
admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
|
PRIMARY | |||
|
5585
Created by
admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
|
PRIMARY | |||
|
2064
Created by
admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
|
PRIMARY | |||
|
DB04571
Created by
admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
|
PRIMARY | |||
|
D014307
Created by
admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
|
PRIMARY | |||
|
28329
Created by
admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
|
PRIMARY | |||
|
TRIOXSALEN
Created by
admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
|
PRIMARY | |||
|
Y6UY8OV51T
Created by
admin on Mon Mar 31 18:31:05 GMT 2025 , Edited by admin on Mon Mar 31 18:31:05 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |